Search
31/12/2024
Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Girolomoni, G, Feldman, SR, Egeberg, A, Puig, L, Jung, J, Jung, H, Lee, Y. Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). JOURNAL OF DERMATOLOGICAL TREATMENT. 2024; 35(1)DOI:10.1080/09546634.2024.2434091. PMID:39626886. IF:3.900(Q1/2D).
31/12/2024
Modelling the spatial risk of malaria through probability distribution of Anopheles maculipennis s.l. and imported cases
Taheri, S, González, MA, Ruiz-López, MJ, Magallanes, S, Delacour-Estrella, S, Lucientes, J, Bueno-Marí, R, Martínez-de la Puente, J, Bravo-Barriga, D, Frontera, E, Polina, A, Martinez-Barciela, Y, Pereira, JM, Garrido, J, Aranda, C, Marzal, A, Ruiz-Arrondo, I, Oteo, JA, Ferraguti, M, Gutíerrez-López, R, Estrada, R, Miranda, MA, Barceló, C, Morchón, R, Montalvo, T, Gangoso, L, Goiri, F, García-Pérez, AL, Ruiz, S, Fernandez-Martinez, B, Gómez-Barroso, D, Figuerola, J. Modelling the spatial risk of malaria through probability distribution of Anopheles maculipennis s.l. and imported cases. Emerging Microbes & Infections. 2024; 13(1)DOI:10.1080/22221751.2024.2343911. PMID:38618930. IF:7.500(Q1/1D).
27/12/2024
Point-of-care additive manufacturing: state of the art and adoption in Spanish hospitals during pre to post COVID-19 era
Valls-Esteve, A, García, RI, Bellmunt, A, Eguiraun, H, Jauregui, I, del Amo, C, Adell-Gomez, N, Krauel, L, Munuera, J. Point-of-care additive manufacturing: state of the art and adoption in Spanish hospitals during pre to post COVID-19 era. 3d Printing In Medicine. 2024; 10(1)DOI:10.1186/s41205-024-00244-9. PMID:39729163. IF:(Q/D).
21/12/2024
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials
Río, P, Zubicaray, J, Navarro, S, Gálvez, E, Sánchez-Domínguez, R, Nicoletti, E, Sebastian, E, Rothe, M, Pujol, R, Bogliolo, M, John-Neek, P, Bastone, AL, Schambach, A, Wang, W, Schmidt, M, Larcher, L, Segovia, JC, Yáñez, RM, Alberquilla, O, Diez, B, Fernández-García, M, García-García, L, Ramírez, M, Galy, A, Lefrere, F, Cavazzana, M, Leblanc, T, de Andoin, NG, López-Almaraz, R, Catala, A, Barquinero, J, Rodríguez-Perales, S, Rao, G, Surrallés, J, Soulier, J, Díaz-de-Heredia, C, Schwartz, JD, Sevilla, J, Bueren, JA. Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. LANCET. 2024; 404(10471)DOI:10.1016/S0140-6736(24)01880-4. PMID:39642902. IF:88.500(Q1/1D).
20/12/2024
Effectiveness of an Exercise and Educational-Based Prehabilitation Program in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy (PREOptimize) on Functional Outcomes: A Randomized Controlled Trial
Casanovas-alvarez, A, Estanyol, B, Ciendones, M, Padròs, J, Cuartero, J, Barnadas, A, García-Valdecasas, B, González-Colom, R, Sebio-García, R, Masià, J. Effectiveness of an Exercise and Educational-Based Prehabilitation Program in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy (PREOptimize) on Functional Outcomes: A Randomized Controlled Trial. PHYSICAL THERAPY. 2024; 104(12)DOI:10.1093/ptj/pzae151. PMID:39423256. IF:3.300(Q1/1D).
19/12/2024
Guillain-Barre syndrome
Leonhard, SE, Papri, N, Querol, L, Rinaldi, S, Shahrizaila, N, Jacobs, BC. Guillain-Barre syndrome. Nature Reviews Disease Primers. 2024; 10(1)DOI:10.1038/s41572-024-00580-4. PMID:39702645. IF:60.600(Q1/1D).